| Derrick S Tooth, MD | |
|
1053 Western Ave, Manchester, ME 04351-3403 | |
| (207) 622-6319 | |
| (207) 622-6654 |
| Full Name | Derrick S Tooth |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 33 Years |
| Location | 1053 Western Ave, Manchester, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1639260847 | NPI | - | NPPES |
| 255890099 | Medicaid | ME | |
| 030440 | Other | ME | ANTHEM |
| 1041053 | Other | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 014663 (Maine) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Maine General Medical Center | Augusta, ME | Hospital |
| Penobscot Bay Medical Center | Rockport, ME | Hospital |
| Redington Fairview General Hospital | Skowhegan, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mainegeneral Medical Center | 1254245715 | 487 |
News Archive
A new Commentary identifies three actionable challenges for translating pharmacomicrobiomics to personalized medicine in 2020.
According to a newly released study people who learned about relaxed breathing and received soothing touch and music before heart surgery were more likely to be alive 6 months after the procedure.
Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling.
There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals.
Apollo Medical Holdings, Inc., an integrated, physician-centric healthcare delivery company, today announced financial results for the 12 months ended January 31, 2014.
› Verified 5 days ago
| Entity Name | Mainegeneral Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669423380 PECOS PAC ID: 1254245715 Enrollment ID: O20031118000718 |
News Archive
A new Commentary identifies three actionable challenges for translating pharmacomicrobiomics to personalized medicine in 2020.
According to a newly released study people who learned about relaxed breathing and received soothing touch and music before heart surgery were more likely to be alive 6 months after the procedure.
Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling.
There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals.
Apollo Medical Holdings, Inc., an integrated, physician-centric healthcare delivery company, today announced financial results for the 12 months ended January 31, 2014.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Derrick S Tooth, MD 9 Pleasant Street, Suite 2, Oakland, ME 04963 Ph: (207) 465-2700 | Derrick S Tooth, MD 1053 Western Ave, Manchester, ME 04351-3403 Ph: (207) 622-6319 |
News Archive
A new Commentary identifies three actionable challenges for translating pharmacomicrobiomics to personalized medicine in 2020.
According to a newly released study people who learned about relaxed breathing and received soothing touch and music before heart surgery were more likely to be alive 6 months after the procedure.
Blueprint Medicines today announced new preclinical data demonstrating that BLU-554, a selective and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4), has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signaling.
There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals.
Apollo Medical Holdings, Inc., an integrated, physician-centric healthcare delivery company, today announced financial results for the 12 months ended January 31, 2014.
› Verified 5 days ago